Arcturus Therapeutics Holdings IncARCT
Price$13.69Intrinsic value$10.9920% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $29.4M-80.7% YoYTTM through 30 Jun 2026
Net Income -$93.3MTTM through 30 Jun 2026
Free Cash Flow -$72.8MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-339.0%
Operating Margin-1,403.7%
Net Margin-317.6%

Returns

-41.1%ROE
-32.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio6.31x
Net Debt-$211.4Mnet cash position
Cash & Equivalents$191.5M

Quality Metrics

Altman Z-Score0.64
Piotroski F-Score1 / 9
FCF Margin-248.0%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $82M
Diluted EPS-$3.33TTM
'21'22'23'24'25
FY2025: $-2.40

Dividend

No dividend

Capital Allocation

Capex Intensity0.3%

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.